The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  A Biologics License Application for ElzonrisTM (also known as tagraxofusp and SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm has been accepted for filing by the United States FDA.…

Continue Reading The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Epigenetic Technology Could Become Useful in Newborn Screening for Primary Immunodeficiency and Monitoring HIV
Rainer_Maiores / Pixabay

Epigenetic Technology Could Become Useful in Newborn Screening for Primary Immunodeficiency and Monitoring HIV

Researchers are exploring a new diagnostic method that could be applied to newborn screening for certain inherited diseases and monitoring of HIV patients. For more detailed information, you can click…

Continue Reading Epigenetic Technology Could Become Useful in Newborn Screening for Primary Immunodeficiency and Monitoring HIV

Results from First Study on Patient-To-Patient Connectivity in Those with FCS

  According to DAIC, Akcea Therapeutics Inc., has recently announced their publication of results from their study analyzing patient-to-patient connectivity towards the management of the rare disease familial chylomicronemia syndrome (FCS).…

Continue Reading Results from First Study on Patient-To-Patient Connectivity in Those with FCS
At Just Weeks Old, a Baby From Auckland is Diagnosed With Aicardi Syndrome and Opsoclonus Myoclonus Syndrome
https://pixabay.com/en/baby-care-child-cute-hand-face-20339/

At Just Weeks Old, a Baby From Auckland is Diagnosed With Aicardi Syndrome and Opsoclonus Myoclonus Syndrome

According to a story from stuff.co.nz, a baby from Auckland has been diagnosed with two extremely rare disorders that only occur in one in every 10 million people. Her name…

Continue Reading At Just Weeks Old, a Baby From Auckland is Diagnosed With Aicardi Syndrome and Opsoclonus Myoclonus Syndrome